AU2017290238B2 - Diprovocims: a new and potent class of TLR agonists - Google Patents
Diprovocims: a new and potent class of TLR agonists Download PDFInfo
- Publication number
- AU2017290238B2 AU2017290238B2 AU2017290238A AU2017290238A AU2017290238B2 AU 2017290238 B2 AU2017290238 B2 AU 2017290238B2 AU 2017290238 A AU2017290238 A AU 2017290238A AU 2017290238 A AU2017290238 A AU 2017290238A AU 2017290238 B2 AU2017290238 B2 AU 2017290238B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- pyrrolidine
- trans
- conhch
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(C(CC1)CN1C(c(cc1)ccc1C(N(C[C@]1C(N[C@@](C2)[C@@]2c2ccccc2)=O)C[C@]1C(N[C@](C1)[C@@]1c1ccccc1)=O)=O)=O)=O Chemical compound *C(C(CC1)CN1C(c(cc1)ccc1C(N(C[C@]1C(N[C@@](C2)[C@@]2c2ccccc2)=O)C[C@]1C(N[C@](C1)[C@@]1c1ccccc1)=O)=O)=O)=O 0.000 description 1
- JWAGHQCWUMRGSV-NNVZUGSQSA-N C[C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N)=O Chemical compound C[C@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(N)=O JWAGHQCWUMRGSV-NNVZUGSQSA-N 0.000 description 1
- IGZRMBGIFXJBAF-HAWHYBLXSA-N O=C(C[C@H](CN(C1)C(c(cc2)ccc2C(N(CC2)C[C@H]2C(NC(C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(NC(C1)[C@@H]1c1ccccc1)=O)NC(C1)[C@@H]1c1ccccc1 Chemical compound O=C(C[C@H](CN(C1)C(c(cc2)ccc2C(N(CC2)C[C@H]2C(NC(C2)[C@H]2c2ccccc2)=O)=O)=O)[C@@H]1C(NC(C1)[C@@H]1c1ccccc1)=O)NC(C1)[C@@H]1c1ccccc1 IGZRMBGIFXJBAF-HAWHYBLXSA-N 0.000 description 1
- YPTVBZSWVIZPRQ-WWXCBJRZSA-N O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@H]1C(NCCc(cc1)ccc1F)=O)NCCc(cc1)ccc1F Chemical compound O=C([C@@H](CN(C1)C(c(cc2)ccc2C(N(C[C@H]2C(N[C@@H](C3)[C@H]3c3ccccc3)=O)C[C@H]2C(N[C@@H](C2)[C@H]2c2ccccc2)=O)=O)=O)[C@H]1C(NCCc(cc1)ccc1F)=O)NCCc(cc1)ccc1F YPTVBZSWVIZPRQ-WWXCBJRZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356314P | 2016-06-29 | 2016-06-29 | |
| US62/356,314 | 2016-06-29 | ||
| PCT/US2017/040028 WO2018005812A1 (en) | 2016-06-29 | 2017-06-29 | Diprovocims: a new and potent class of tlr agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017290238A1 AU2017290238A1 (en) | 2018-12-13 |
| AU2017290238B2 true AU2017290238B2 (en) | 2021-02-18 |
Family
ID=60787607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017290238A Active AU2017290238B2 (en) | 2016-06-29 | 2017-06-29 | Diprovocims: a new and potent class of TLR agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040959B2 (https=) |
| EP (1) | EP3445758B1 (https=) |
| JP (1) | JP6964298B2 (https=) |
| KR (1) | KR102522730B1 (https=) |
| CN (1) | CN109641878B (https=) |
| AU (1) | AU2017290238B2 (https=) |
| BR (1) | BR112018077397A2 (https=) |
| CA (1) | CA3026178C (https=) |
| IL (1) | IL263388B (https=) |
| WO (1) | WO2018005812A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164445A (zh) * | 2018-08-02 | 2021-07-23 | 得克萨斯系统大学评议会 | Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病 |
| JP2023527792A (ja) | 2020-05-27 | 2023-06-30 | アキシャル セラピューティクス，インク． | Ｔｌｒ２調節剤化合物、医薬組成物、及びそれらの使用 |
| US20250367166A1 (en) * | 2022-04-29 | 2025-12-04 | The Scripps Research Institute | Next generation diprovocims that activate the innate and adaptive immune response |
| US20260091126A1 (en) * | 2022-09-20 | 2026-04-02 | The Curators Of The University Of Missouri | Amino acid-modified lipids for rna delivery |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100173969A1 (en) * | 2001-08-08 | 2010-07-08 | Pepys Mark B | Therapeutic agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
| PE20071079A1 (es) | 2005-11-15 | 2007-12-16 | Cytokinetics Inc | Compuestos de piperidina como inhibidores de la proliferacion celular |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| EP2958889B1 (en) | 2013-02-25 | 2017-03-22 | The Scripps Research Institute | Neoseptins: small molecule adjuvants |
| US9918959B2 (en) | 2014-08-06 | 2018-03-20 | The Board Of Regents Of The University Of Texas System | TLR-independent small molecule adjuvants |
-
2017
- 2017-06-29 KR KR1020197002820A patent/KR102522730B1/ko active Active
- 2017-06-29 BR BR112018077397A patent/BR112018077397A2/pt unknown
- 2017-06-29 EP EP17821259.3A patent/EP3445758B1/en active Active
- 2017-06-29 CN CN201780040830.9A patent/CN109641878B/zh active Active
- 2017-06-29 CA CA3026178A patent/CA3026178C/en active Active
- 2017-06-29 WO PCT/US2017/040028 patent/WO2018005812A1/en not_active Ceased
- 2017-06-29 JP JP2018568338A patent/JP6964298B2/ja active Active
- 2017-06-29 US US16/303,043 patent/US11040959B2/en active Active
- 2017-06-29 AU AU2017290238A patent/AU2017290238B2/en active Active
-
2018
- 2018-11-29 IL IL263388A patent/IL263388B/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100173969A1 (en) * | 2001-08-08 | 2010-07-08 | Pepys Mark B | Therapeutic agent |
Non-Patent Citations (1)
| Title |
|---|
| SCI. ADV., 2015, vol. 1, no. 3, pages 1 - 12 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641878B (zh) | 2021-09-14 |
| CA3026178C (en) | 2024-05-21 |
| WO2018005812A1 (en) | 2018-01-04 |
| KR20190014133A (ko) | 2019-02-11 |
| CA3026178A1 (en) | 2018-01-04 |
| IL263388A (en) | 2018-12-31 |
| JP6964298B2 (ja) | 2021-11-10 |
| EP3445758A1 (en) | 2019-02-27 |
| US11040959B2 (en) | 2021-06-22 |
| EP3445758A4 (en) | 2019-09-25 |
| BR112018077397A2 (pt) | 2019-10-01 |
| KR102522730B1 (ko) | 2023-04-19 |
| AU2017290238A1 (en) | 2018-12-13 |
| CN109641878A (zh) | 2019-04-16 |
| JP2019519574A (ja) | 2019-07-11 |
| IL263388B (en) | 2021-02-28 |
| EP3445758B1 (en) | 2020-11-04 |
| US20200207742A1 (en) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7829523B2 (ja) | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 | |
| US6559146B1 (en) | Aminophenoxyacetic acid derivatives as neuroprotectants | |
| AU2017290238B2 (en) | Diprovocims: a new and potent class of TLR agonists | |
| CN109415387B (zh) | 精氨酸酶抑制剂及其治疗应用 | |
| CN113150016A (zh) | 用于抑制精氨酸酶活性的组合物和方法 | |
| US20150018340A1 (en) | Pipecolate-diketoamides for treatment of psychiatric disorders | |
| JP6643484B2 (ja) | ７−オキソ−６−（スルホオキシ）−１，６−ジアザビシクロ［３．２．１］オクタン−２−カルボキサミド含有化合物および細菌感染症の治療におけるそれらの使用 | |
| US20230373937A1 (en) | Inhibitors of spinster homolog 2 (spns2) for use in therapy | |
| US20220213099A1 (en) | Prodrug compounds | |
| CA3196221A1 (en) | Conjugated tlr7 and nod2 agonists | |
| TW442469B (en) | Fibrinogen receptor antagonists having substituted β-amino acid residues and pharmaceutical compositions comprising the same | |
| IL324431A (en) | Anti-hiv compounds | |
| ES2345377B1 (es) | Compuestos aminociclitoles, procedimiento de obtencion y usos. | |
| CN120603813A (zh) | 2-氨基-n-(4-氨基-3,4-二氧代-1-(2-氧代吡咯烷-3-基)丁-2-基)苯甲酰胺衍生物作为蛋白酶抑制剂用于治疗或预防冠状病毒感染 | |
| RU2637928C2 (ru) | Производные арилциклоалкиламинов, нейропротектор (варианты), вещество, обладающее сочетанным нейропротекторным, анальгетическим и антидепрессивным действием, фармацевтические композиции на его основе | |
| US20250367166A1 (en) | Next generation diprovocims that activate the innate and adaptive immune response | |
| CN101990536B (zh) | 基于吡咯烷的化合物 | |
| WO2002057235A1 (en) | Process for preparation of benzylpiperidine compounds | |
| Wu | Modulators of Toll-like Receptors-4 and-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |